José Baselga
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 155
- HER2/EGFR in Cancer Research 99
- Cancer Treatment and Pharmacology 35
- Colorectal Cancer Treatments and Studies 21
-
- Lung Cancer Treatments and Mutations 35
- Advanced Breast Cancer Therapies 14
- Co-authors
- John M. Mendelsohn (7 shared papers)Larry Norton (10 shared papers)Mark Daniel Pegram (2 shared papers)Wolfgang EIERMANN (7 shared papers)Brian R Leyland-Jones (3 shared papers)Thomas Henry Fleming (1 shared paper)Virginia E. Paton (1 shared paper)Steven Shak (1 shared paper)
- Journals
- Journal of Clinical Oncology (37 papers)Annals of Oncology (27 papers)Clinical Cancer Research (26 papers)European Journal of Cancer (8 papers)Cancer Research (8 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
José Baselga
234 papers receiving 58.4k citations
José Baselga's Hit Papers
Peers
Comparison fields: 5 of 167
- Oncology 34.1k
- Cancer Research 11.0k
- Radiology, Nuclear Medicine and Imaging 10.5k
- Pulmonary and Respiratory Medicine 13.3k
- Genetics 3.0k
Countries citing papers authored by José Baselga
This map shows the geographic impact of José Baselga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Baselga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Baselga more than expected).
Fields of papers citing papers by José Baselga
This network shows the impact of papers produced by José Baselga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Baselga. The network helps show where José Baselga may publish in the future.
Co-authors
The 25 scholars most cited alongside José Baselga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 236 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 9395 |
| 2 | The landscape of somatic copy-number alteration across human cancers Hit paper breakdown → | 2010 | 3151 |
| 3 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 3075 |
| 4 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2003 | 2525 |
| 5 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 2024 |
| 6 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Hit paper breakdown → | 2015 | 1467 |
| 7 | The EGF receptor family as targets for cancer therapy Hit paper breakdown → | 2000 | 1166 |
| 8 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Hit paper breakdown → | 2017 | 1101 |
| 9 | Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer Hit paper breakdown → | 2003 | 1088 |
| 10 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 1002 |
| 11 | Sequence analysis of mutations and translocations across breast cancer subtypes Hit paper breakdown → | 2012 | 1000 |
| 12 | Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Hit paper breakdown → | 2007 | 991 |
| 13 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Hit paper breakdown → | 2009 | 975 |
| 14 | Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Hit paper breakdown → | 1998 | 860 |
| 15 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Hit paper breakdown → | 2015 | 849 |
| 16 | AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity Hit paper breakdown → | 2011 | 828 |
| 17 | Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer Hit paper breakdown → | 2010 | 781 |
| 18 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 732 |
| 19 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer Hit paper breakdown → | 2007 | 730 |
| 20 | 2002 | 665 |
About José Baselga
José Baselga is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research and Genetics, having authored 236 papers that have together received 60.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (99 papers), Cancer Treatment and Pharmacology (35 papers), Lung Cancer Treatments and Mutations (35 papers), Monoclonal and Polyclonal Antibodies Research (31 papers), Colorectal Cancer Treatments and Studies (21 papers), PI3K/AKT/mTOR signaling in cancer (17 papers), Advanced Breast Cancer Therapies (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). The work is most often cited by research in Oncology (34.1k citations), Cancer Research (11.0k citations), Radiology, Nuclear Medicine and Imaging (10.5k citations), Pulmonary and Respiratory Medicine (13.3k citations) and Genetics (3.0k citations). José Baselga has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include John M. Mendelsohn, Larry Norton, Mark Daniel Pegram, Wolfgang EIERMANN, Brian R Leyland-Jones, Thomas Henry Fleming, Virginia E. Paton, Steven Shak, Janet M. Wolter and Alex Bajamonde. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, European Journal of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.